Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Globenewswire
Clinical Efficacy of NDV-01: A Phase 2 study presented at AUA2025 showed that 90% of patients with high-grade non-muscle invasive bladder cancer achieved disease-free status after treatment with NDV-01, indicating strong clinical activity and tolerability.
Potential Impact on Treatment: NDV-01, a sustained-release formulation of gemcitabine and docetaxel, aims to simplify outpatient treatment for bladder cancer and may significantly improve patient outcomes due to its ease of administration and robust efficacy across different patient groups.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
